학술논문

Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer
Document Type
Article
Source
In Annals of Oncology August 2020 31(8):1001-1010
Subject
Breast tumors
Language
ISSN
0923-7534